Skip to main content
OpenTrials
Completed

NCT Number: NCT01304043

French Observatory of Rare Malignant Tumors of the Ovary

To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.

Completed

Looking for future studies?

Notify Me

Key information

About this study

  • to establish prognosis factors for the disease
  • to proceed in a centralised examination of histologic laminas
  • to reach in the long-term and homogenous follow-up of the patients
  • to follow-up the long-term toxicities of the treatments given
  • to analyse and follow-up the later fertility of the patients
  • to evaluate the interest of setting a multi-disciplinary discussion forum on the Web

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age > 18 years old
  • germinal or sexual cords ovary tumors histologically proven
  • first line or relapse treatment
  • written informed consent

Exclusion criteria

  • mental ineptitude to understand and follow the study

Treatment and study plan

chemotherapies protocols

Drug

Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV

Sponsors and collaborators

Lead sponsor

ARCAGY/ GINECO GROUP

Other

Registry information

Official study title

Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)

Important dates

Study start
2002
Study completion
2011
First posted
Feb 25, 2011
Registry last updated
Apr 20, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.